Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Bristol Myers Squibb Expands ALS Partnership with Insitro, Commits Over $2 Billion

Bristol Myers Squibb (BMS) has announced a significant extension of its collaboration with artificial intelligence specialist Insitro, focusing on the development of novel treatments for amyotrophic lateral sclerosis (ALS). The expanded partnership, which builds on a relationship first established in 2020, could see Insitro receive more than $2 billion in milestone payments and royalties.

NoahAI News10/16/2025

BioCryst Acquires Astria Therapeutics for $700M, Bolstering HAE Portfolio

BioCryst Pharmaceuticals has announced a $700 million acquisition of Astria Therapeutics, significantly expanding its presence in the hereditary angioedema (HAE) market. The deal, expected to close in the first quarter of 2026, will give BioCryst control of navenibart, a promising long-acting injectable drug for HAE currently in Phase III development.

NoahAI News10/16/2025

FDA Awards Platform Technology Designation to Krystal Biotech, Validating HSV-1 Vector Platform

The U.S. Food and Drug Administration (FDA) has granted its second platform technology designation to Krystal Biotech for the company's non-replicating HSV-1 viral vector, used in the delivery of its gene therapies. This development comes after the FDA revoked Sarepta Therapeutics' platform designation in July, following a series of deaths linked to their adeno-associated virus vector platform.

NoahAI News10/16/2025

Abbott Prepares to Enter PFA Market with Volt System, Expands Diabetes Portfolio

Abbott Laboratories is gearing up to make significant strides in both cardiac ablation and diabetes care, as revealed in the company's recent third-quarter earnings call. CEO Robert Ford outlined Abbott's strategic positioning in the competitive pulsed field ablation (PFA) market and highlighted upcoming innovations in continuous glucose monitoring technology.

NoahAI News10/16/2025

Pelage Pharmaceuticals Secures $120 Million for Novel Hair Loss Treatment

Pelage Pharmaceuticals, a Los Angeles-based startup, has closed a $120 million Series B funding round to advance its innovative topical gel therapy for hair loss. The funding, led by Arch Venture Partners and GV (formerly Google Ventures), marks a significant milestone in the development of a potentially groundbreaking treatment for androgenetic alopecia, the most common form of hair loss.

NoahAI News10/16/2025

Town Hall Ventures Raises $440M for AI-Focused Health Equity Fund

Town Hall Ventures (THV) has announced the successful raise of its fourth fund, securing $440 million in capital commitments. This latest fund aims to support artificial intelligence (AI) startups dedicated to bringing innovative care models to underserved communities, marking a significant step in the venture firm's mission to address health equity through technology.

NoahAI News10/16/2025

AstraZeneca Invests $445M to Boost Lokelma Production in Texas

AstraZeneca has announced a significant investment of $445 million to expand its manufacturing capabilities for the hyperkalemia treatment Lokelma at its facility in Coppell, Texas. This move comes as part of the company's broader $50 billion investment plan in the United States over the next five years.

NoahAI News10/16/2025

GSK and Scynexis Resolve Brexafemme Trial Dispute with $22M Settlement

GSK and Scynexis have reached an agreement to resolve their dispute over the phase 3 MARIO study of the antifungal medication Brexafemme (ibrexafungerp) in invasive candidiasis. The resolution includes a $22 million payment from GSK to Scynexis and marks a significant development in their ongoing collaboration.

NoahAI News10/16/2025

CVS Expands Footprint with Acquisition of 63 Rite Aid Stores

CVS Health has completed a significant acquisition deal, purchasing 63 Rite Aid and Bartell Drugs stores across Idaho, Oregon, and Washington. This strategic move comes in the wake of Rite Aid's recent bankruptcy filing and marks a substantial expansion for CVS in the Pacific Northwest region.

NoahAI News10/16/2025

Stereotaxis and CardioFocus Join Forces to Develop Robotic Pulsed Field Ablation System

In a significant move that combines robotic precision with cutting-edge cardiac treatment technology, Stereotaxis and CardioFocus have announced a partnership to develop a robotic pulsed field ablation (PFA) system for treating cardiac arrhythmias. This collaboration marks a notable advancement in the field of electrophysiology, promising to enhance the safety and efficacy of arrhythmia treatments.

NoahAI News10/16/2025

Biopharma Job Market: Navigating Extended Search Times and Strategies for Success

In the current pharmaceutical industry landscape, job seekers are facing extended periods of unemployment, with recent data indicating that securing a position in the biopharma sector often requires patience and persistence. A comprehensive look at the job market reveals both challenges and opportunities for professionals in this field.

NoahAI News10/16/2025

NewAmsterdam Partners with Caristo Diagnostics for AI-Powered Cardiovascular Trial

NewAmsterdam Pharma has announced a strategic partnership with Caristo Diagnostics, leveraging artificial intelligence to enhance its upcoming cardiovascular drug trial. The collaboration aims to evaluate the efficacy of NewAmsterdam's cholesterol-lowering drug candidate, obicetrapib, in combination with ezetimibe.

NoahAI News10/16/2025

«1...21 22 23...67 »